Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
ALK-positive NSCLC
Biomarkers
Cell-free DNA
DNA methylation
Epigenetics
Liquid biopsy
cfMeDIP-seq
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
02 12 2022
02 12 2022
Historique:
received:
29
09
2022
accepted:
25
11
2022
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
7
12
2022
Statut:
epublish
Résumé
DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer patients represent promising biomarkers for minimally invasive tumor detection. The high abundance of cancer-associated 5-mC alterations permits parallel and highly sensitive assessment of multiple 5-mC biomarkers. Here, we performed genome-wide 5-mC profiling in the plasma of metastatic ALK-rearranged non-small cell lung cancer (NSCLC) patients receiving tyrosine kinase inhibitor therapy. We established a strategy to identify ALK-specific 5-mC changes from cfDNA and demonstrated the suitability of the identified markers for cancer detection, prognosis, and therapy monitoring. Longitudinal plasma samples (n = 79) of 21 ALK-positive NSCLC patients and 13 healthy donors were collected alongside 15 ALK-positive tumor tissue and 10 healthy lung tissue specimens. All plasma and tissue samples were analyzed by cell-free DNA methylation immunoprecipitation sequencing to generate genome-wide 5-mC profiles. Information on genomic alterations (i.e., somatic mutations/fusions and copy number alterations) determined in matched plasma samples was available from previous studies. We devised a strategy that identified tumor-specific 5-mC biomarkers by reducing 5-mC background signals derived from hematopoietic cells. This was followed by differential methylation analysis (cases vs. controls) and biomarker validation using 5-mC profiles of ALK-positive tumor tissues. The resulting 245 differentially methylated regions were enriched for lung adenocarcinoma-specific 5-mC patterns in TCGA data and indicated transcriptional repression of several genes described to be silenced in NSCLC (e.g., PCDH10, TBX2, CDO1, and HOXA9). Additionally, 5-mC-based tumor DNA (5-mC score) was highly correlated with other genomic alterations in cell-free DNA (Spearman, ρ > 0.6), while samples with high 5-mC scores showed significantly shorter overall survival (log-rank p = 0.025). Longitudinal 5-mC scores reflected radiologic disease assessments and were significantly elevated at disease progression compared to the therapy start (p = 0.0023). In 7 out of 8 instances, rising 5-mC scores preceded imaging-based evaluation of disease progression. We demonstrated a strategy to identify 5-mC biomarkers from the plasma of cancer patients and integrated them into a quantitative measure of cancer-associated 5-mC alterations. Using longitudinal plasma samples of ALK-positive NSCLC patients, we highlighted the suitability of cfDNA methylation for prognosis and therapy monitoring.
Sections du résumé
BACKGROUND
DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer patients represent promising biomarkers for minimally invasive tumor detection. The high abundance of cancer-associated 5-mC alterations permits parallel and highly sensitive assessment of multiple 5-mC biomarkers. Here, we performed genome-wide 5-mC profiling in the plasma of metastatic ALK-rearranged non-small cell lung cancer (NSCLC) patients receiving tyrosine kinase inhibitor therapy. We established a strategy to identify ALK-specific 5-mC changes from cfDNA and demonstrated the suitability of the identified markers for cancer detection, prognosis, and therapy monitoring.
METHODS
Longitudinal plasma samples (n = 79) of 21 ALK-positive NSCLC patients and 13 healthy donors were collected alongside 15 ALK-positive tumor tissue and 10 healthy lung tissue specimens. All plasma and tissue samples were analyzed by cell-free DNA methylation immunoprecipitation sequencing to generate genome-wide 5-mC profiles. Information on genomic alterations (i.e., somatic mutations/fusions and copy number alterations) determined in matched plasma samples was available from previous studies.
RESULTS
We devised a strategy that identified tumor-specific 5-mC biomarkers by reducing 5-mC background signals derived from hematopoietic cells. This was followed by differential methylation analysis (cases vs. controls) and biomarker validation using 5-mC profiles of ALK-positive tumor tissues. The resulting 245 differentially methylated regions were enriched for lung adenocarcinoma-specific 5-mC patterns in TCGA data and indicated transcriptional repression of several genes described to be silenced in NSCLC (e.g., PCDH10, TBX2, CDO1, and HOXA9). Additionally, 5-mC-based tumor DNA (5-mC score) was highly correlated with other genomic alterations in cell-free DNA (Spearman, ρ > 0.6), while samples with high 5-mC scores showed significantly shorter overall survival (log-rank p = 0.025). Longitudinal 5-mC scores reflected radiologic disease assessments and were significantly elevated at disease progression compared to the therapy start (p = 0.0023). In 7 out of 8 instances, rising 5-mC scores preceded imaging-based evaluation of disease progression.
CONCLUSION
We demonstrated a strategy to identify 5-mC biomarkers from the plasma of cancer patients and integrated them into a quantitative measure of cancer-associated 5-mC alterations. Using longitudinal plasma samples of ALK-positive NSCLC patients, we highlighted the suitability of cfDNA methylation for prognosis and therapy monitoring.
Identifiants
pubmed: 36461127
doi: 10.1186/s13148-022-01387-4
pii: 10.1186/s13148-022-01387-4
pmc: PMC9719130
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Biomarkers, Tumor
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
163Informations de copyright
© 2022. The Author(s).
Références
Bioinformatics. 2016 Jan 15;32(2):289-91
pubmed: 26424858
Genome Med. 2020 Feb 28;12(1):23
pubmed: 32111235
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nat Genet. 2017 Apr;49(4):635-642
pubmed: 28263317
Nature. 2018 Nov;563(7732):579-583
pubmed: 30429608
Epigenomics. 2020 Aug;12(15):1317-1332
pubmed: 32867540
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Nat Med. 2019 May;25(5):738-743
pubmed: 31011204
Ann Oncol. 2021 Sep;32(9):1167-1177
pubmed: 34176681
Nucleic Acids Res. 2018 Jan 4;46(D1):D1144-D1149
pubmed: 29099951
Clin Cancer Res. 2019 Nov 15;25(22):6662-6670
pubmed: 31358542
Clin Cancer Res. 2018 Mar 1;24(5):1038-1047
pubmed: 29217530
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Cell Syst. 2016 Nov 23;3(5):491-495.e5
pubmed: 27863955
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
Oncotarget. 2017 Aug 4;8(40):68230-68241
pubmed: 28978111
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Cancers (Basel). 2020 Apr 11;12(4):
pubmed: 32290439
Nat Cancer. 2022 Oct;3(10):1260-1270
pubmed: 35941262
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322500
Int J Cancer. 2019 Jan 1;144(1):190-199
pubmed: 30255938
N Engl J Med. 2008 Mar 13;358(11):1148-59
pubmed: 18337604
Nat Med. 2020 Jul;26(7):1044-1047
pubmed: 32572265
NPJ Precis Oncol. 2021 Dec 7;5(1):100
pubmed: 34876698
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nucleic Acids Res. 2018 Sep 6;46(15):e89
pubmed: 29897492
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Int J Cancer. 2018 Jun 15;142(12):2589-2598
pubmed: 29363116
Nat Med. 2020 Jul;26(7):1114-1124
pubmed: 32483360
Pharmaceuticals (Basel). 2021 Jan 21;14(2):
pubmed: 33494549
Cancer Med. 2015 Oct;4(10):1536-46
pubmed: 26276761
Clin Cancer Res. 2021 Aug 1;27(15):4230-4244
pubmed: 34158359
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Nat Protoc. 2019 Oct;14(10):2749-2780
pubmed: 31471598
J Clin Invest. 2014 Jan;124(1):17-23
pubmed: 24382385
Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):E5503-12
pubmed: 26392541
Ann Oncol. 2017 Apr 1;28(4):791-797
pubmed: 28039177
Cancer Med. 2022 Aug;11(15):2944-2956
pubmed: 35437925
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
BMC Genomics. 2017 Jan 25;18(Suppl 1):1045
pubmed: 28198667
Lancet. 2018 Sep 1;392(10149):777-786
pubmed: 30100054
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Clin Cancer Res. 2018 Jun 15;24(12):2758-2770
pubmed: 29599410
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
EBioMedicine. 2020 Dec;62:103103
pubmed: 33161228
JCO Precis Oncol. 2018;2018:
pubmed: 29376144
Semin Cancer Biol. 2018 Aug;51:116-128
pubmed: 28919484
Nat Biotechnol. 2021 Dec;39(12):1537-1547
pubmed: 34294911
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Bioinformatics. 2014 Jan 15;30(2):284-6
pubmed: 24227674
Cell Res. 2017 Oct;27(10):1231-1242
pubmed: 28820176
Bioinformatics. 2017 Aug 01;33(15):2381-2383
pubmed: 28369316
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Nat Med. 2020 Jul;26(7):1041-1043
pubmed: 32572266
PLoS Genet. 2011 Mar;7(3):e1001356
pubmed: 21483804
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34
pubmed: 26976580
Transl Lung Cancer Res. 2021 May;10(5):2118-2131
pubmed: 34164264
Brief Bioinform. 2017 Sep 1;18(5):761-773
pubmed: 27436122
Clin Epigenetics. 2020 Mar 5;12(1):39
pubmed: 32138766
Nat Commun. 2018 Nov 29;9(1):5068
pubmed: 30498206
Genet Med. 2020 Aug;22(8):1366-1373
pubmed: 32341571
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Rev Clin Oncol. 2020 Nov;17(11):655-656
pubmed: 32732909